M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev
{"title":"olokizumab与tocilizumab在COVID-19住院患者中的比较疗效","authors":"M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev","doi":"10.32756/0869-5490-2022-3-9-15","DOIUrl":null,"url":null,"abstract":"To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative efficacy of olokizumab and tocilizumab in hospitalized patients with COVID-19\",\"authors\":\"M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev\",\"doi\":\"10.32756/0869-5490-2022-3-9-15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"79 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2022-3-9-15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2022-3-9-15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparative efficacy of olokizumab and tocilizumab in hospitalized patients with COVID-19
To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
